Literature DB >> 21726921

Discovery of 6-substituted indole-3-glyoxylamides as lead antiprion agents with enhanced cell line activity, improved microsomal stability and low toxicity.

Mark J Thompson1, Jennifer C Louth, Steven Ferrara, Matthew P Jackson, Fiona J Sorrell, Edward J Cochrane, Joel Gever, Sarah Baxendale, B Michael Silber, Henry H Roehl, Beining Chen.   

Abstract

A series of highly potent indole-3-glyoxylamide based antiprion agents was previously characterized, focusing on optimization of structure-activity relationship (SAR) at positions 1-3 of the indole system. New libraries interrogating the SAR at indole C-4 to C-7 now demonstrate that introducing electron-withdrawing substituents at C-6 may improve biological activity by up to an order of magnitude, and additionally confer higher metabolic stability. For the present screening libraries, both the degree of potency and trends in SAR were consistent across two cell line models of prion disease, and the large majority of compounds showed no evidence of toxic effects in zebrafish. The foregoing observations thus make the indole-3-glyoxylamides an attractive lead series for continuing development as potential therapeutic agents against prion disease.
Copyright © 2011 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21726921     DOI: 10.1016/j.ejmech.2011.06.013

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  7 in total

1.  Prion and Prion-like Diseases in Humans: Poster Abstracts.

Authors: 
Journal:  Prion       Date:  2013 Apr/May       Impact factor: 3.931

2.  Identifying diverse metal oxide nanomaterials with lethal effects on embryonic zebrafish using machine learning.

Authors:  Richard Liam Marchese Robinson; Haralambos Sarimveis; Philip Doganis; Xiaodong Jia; Marianna Kotzabasaki; Christiana Gousiadou; Stacey Lynn Harper; Terry Wilkins
Journal:  Beilstein J Nanotechnol       Date:  2021-11-29       Impact factor: 3.649

3.  Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson's disease.

Authors:  Jens Wagner; Sergey Ryazanov; Andrei Leonov; Johannes Levin; Song Shi; Felix Schmidt; Catharina Prix; Francisco Pan-Montojo; Uwe Bertsch; Gerda Mitteregger-Kretzschmar; Markus Geissen; Martin Eiden; Fabienne Leidel; Thomas Hirschberger; Andreas A Deeg; Julian J Krauth; Wolfgang Zinth; Paul Tavan; Jens Pilger; Markus Zweckstetter; Tobias Frank; Mathias Bähr; Jochen H Weishaupt; Manfred Uhr; Henning Urlaub; Ulrike Teichmann; Matthias Samwer; Kai Bötzel; Martin Groschup; Hans Kretzschmar; Christian Griesinger; Armin Giese
Journal:  Acta Neuropathol       Date:  2013-04-19       Impact factor: 17.088

4.  2-Aminothiazoles with improved pharmacotherapeutic properties for treatment of prion disease.

Authors:  Zhe Li; B Michael Silber; Satish Rao; Joel R Gever; Clifford Bryant; Alejandra Gallardo-Godoy; Elena Dolghih; Kartika Widjaja; Manuel Elepano; Matthew P Jacobson; Stanley B Prusiner; Adam R Renslo
Journal:  ChemMedChem       Date:  2013-03-18       Impact factor: 3.466

5.  Antiprion compounds that reduce PrP(Sc) levels in dividing and stationary-phase cells.

Authors:  B Michael Silber; Joel R Gever; Zhe Li; Alejandra Gallardo-Godoy; Adam R Renslo; Kartika Widjaja; John J Irwin; Satish Rao; Matthew P Jacobson; Sina Ghaemmaghami; Stanley B Prusiner
Journal:  Bioorg Med Chem       Date:  2013-09-18       Impact factor: 3.641

6.  Optimization of Arylamides as Novel, Potent and Brain-penetrant Antiprion Lead Compounds.

Authors:  Zhe Li; Satish Rao; Joel R Gever; Kartika Widjaja; Stanley B Prusiner; B Michael Silber
Journal:  ACS Med Chem Lett       Date:  2013-07-11       Impact factor: 4.345

7.  Development of highly potent melanogenesis inhibitor by in vitro, in vivo and computational studies.

Authors:  Qamar Abbas; Zaman Ashraf; Mubashir Hassan; Humaira Nadeem; Muhammad Latif; Samina Afzal; Sung-Yum Seo
Journal:  Drug Des Devel Ther       Date:  2017-07-05       Impact factor: 4.162

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.